Details

Autor(en) / Beteiligte

• Funkhouser, Avery T.
• Shealy, Jonah C.
• Kesic, Alexandra E.
• Blair, Bailey B.
• Martin, Julie C.
• Arthur, Connie M.
• Funk, Christopher R.
• Edenfield, W. Jeffery
• Blenda, Anna V.

Titel

Abstract 2192: Potential of galectin-7 as differentiating biomarker of lung cancer subtypes

Ist Teil von

• Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.2192-2192

Erscheinungsjahr

2023

Quelle

Electronic Journals Library

Beschreibungen/Notizen

• Abstract Background. Lung cancer is the leading cause of cancer-related death in both men and women in the United States. Non-small Cell Lung Cancer is the most prevalent and includes adenocarcinoma (AD), and squamous cell lung cancers. The unique cellular biology of these cancers could potentially allow for serological detection and identification via tissue specific protein markers. Galectins are a group of β-galactoside binding proteins which are known to be alternatively expressed in cancers and are being studied for their biomarker potential. Galectin-7 is expressed in epithelial tissues as well as in all layers of the epidermis as it is normally highly expressed by squamous cells. Purpose. We are evaluating potential of galectin-7 to be used as a serum biomarker and delineator of several lung cancer subtypes. Methods. The serum concentrations of galectin-7 were measured in 96 cancer patients using ELISA. Twenty-eight samples were from adenocarcinoma lung cancer patients, 25 were from squamous cell lung carcinomas patients, 19 were from all other types of lung cancer, and 28 were from other squamous cell carcinomas of non-pulmonary origin. The serum galectin-7 concentrations in cancer patients were compared amongst themselves by their histological subtypes. One-way analysis was performed using Student’s t-test for pairwise comparisons. Results. Galectin-7 concentrations were significantly elevated in serum samples from squamous cell lung cancer patients (n=25; mean, 1.91 ng/mL) relative to adenocarcinoma lung cancer patients (n=24; mean, 1.02; p-value, 0.0149). Additionally, levels of galectin-7 in samples of squamous cell lung carcinomas were higher than samples of squamous cell carcinomas of non-pulmonary origin (n=28; mean, 0.33 ng/mL, p-value, <0.0001). These results show that serum galectin-7 is increased in patients with squamous cell lung cancer compared to adenocarcinoma lung cancer. Conclusion. Potential clinical applications of this study include the measurement of galectin-7 in blood samples of cancer patients to aid in cancer screening and tumor type identification. Further explorations comprise measuring serum concentrations of galectin-7 by stage of squamous cell lung cancer and histological subtype (keratinizing, non-keratinizing, and basaloid) to determine a more nuanced understanding of the tumor molecular biology. Citation Format: Avery T. Funkhouser, Jonah C. Shealy, Alexandra E. Kesic, Bailey B. Blair, Julie C. Martin, Connie M. Arthur, Christopher R. Funk, W. Jeffery Edenfield, Anna V. Blenda. Potential of galectin-7 as differentiating biomarker of lung cancer subtypes [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2192.